UROGENITAL SYNDROME IN MENOPAUSE: THERAPY POSSIBILITIES
- Autores: Balan V.E.1, Kovaleva L.A.2,3
-
Afiliações:
- Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Russian Federation
- Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation
- I.M. Sechenov First Moscow State University, Ministry of Health of the Russian Federation
- Edição: Nº 5 (2015)
- Páginas: 104-108
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247456
- ID: 247456
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The paper presents a literature review covering the current aspects of terminology, classification, pathogenesis, and possibilities for therapy of urogenital disorders in menopausal women. It shows the susceptibility of the lower urogenital tract to sex steroids, the implication of which in the genesis of vaginal and urinary symptoms is beyond question. The efficiency of systemic and local hormone replacement therapy and different treatment regimens is considered.
Texto integral
Sobre autores
Vera Balan
Moscow Regional Research Institute of Obstetrics and Gynecology, Ministry of Health of the Russian FederationMD, Professor, Head of the Outpatient Department of Defense Moscow 101000, Pokrovka str. 22a, Russia
Larisa Kovaleva
Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation; I.M. Sechenov First Moscow State University, Ministry of Health of the Russian FederationPhD, Department of Gynecological Endocrinology Moscow 117997, Ac. Oparina str. 4, Russia; Moscow 119991, Bolshaya Pirogovskaya str. 2 bld. 4, Russia
Bibliografia
- Балан В.Е., Сметник В.П., Анкирская А.С. и др. Урогенитальные расстройства в климактерии. В кн.: Сметник В.П., ред. Медицина климактерия. Ярославль: Литера; 2006: 217-90.
- Calleja-Agius J., Brincat M.P. Urogenital atrophy. Climacteric. 2009; 12(4): 279-85.
- Barlow D.H., Cardozo L.D., Francis R.M., Griffin M., Hart D.M., Stephens E., Sturdee D. W. Urogenital ageing and its effect on sexual health in older British women. Br. J. Obstet. Gynaecol. 1997;104(1): 87-91.
- Al-Baghdadi O., Ewies A.A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009; 12(2): 91-105.
- Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause. 2008; 15(4): 584-603.
- Gebhart J.B., Rickard D.J., Barrett T.J., Lesnick T.G., Webb M.J., Podratz K.C., Spelsberg T.C. Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am. J. Obstet. Gynecol. 2001; 185(6): 1325-30; discussion 1330-1.
- Cavallini A., Dinaro E., Giocolano A., Caringella A.M., Ferreri R., Tutino V., Loverro G. Estrogen receptor (ER) and ER-related receptor expressoin in normal and atrophic human vagina. Maturitas. 2008; 59(4): 219-25.
- Raghunandan C., Agrawal S., Dubey P., Choudhury M., Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J. Sex. Med. 2010; 7(3): 1284-90.
- Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013; 20(9): 888-902; quiz 903-4.
- Johnston S.L., Farrell S.A., Bouchard C., Farrell S.A., Beckerson L.A., Comeau M. et al.; SOGC Joint Committee-Clinical Practice Gynaecology and Urogynaecology. The detection and management of vaginal atrophy. J. Obstet. Gynaecol. Can. 2004; 26(5): 503-15.
- Burger H., Archer D., Barlow D., Birkhäuser M., Calaf-Alsina J., Gambacciani M. et al. Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric. 2004; 7(2): 210-6.
- Santen R.J., Allred D.C., Ardoin S.P., Archer D.F., Boyd N., Braunstein G.D. et al.; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 2010; 95(7, Suppl.1): S1-66.
- Weisberg E., Ayton R., Darling G., Farrell E., Murkies A., O’Neill S. et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Cimacteric. 2005; 8(1): 83-92.